Literature DB >> 24580043

Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment.

Magdy El-Salhy1, Jan Gunnar Hatlebakk, Odd Helge Gilja, Trygve Hausken.   

Abstract

The diagnosis of irritable bowel syndrome (IBS) remains a diagnosis of exclusion, whereby an extensive investigation is performed to exclude other organic diseases that may explain the symptoms of patients. Attempts to have a positive diagnosis based on symptom assessments failed to achieve widely use in clinical practice. Abnormalities in the gastrointestinal endocrine cells in IBS patients have been reported recently, providing evidence that IBS is an organic disorder, and opening the door to the use of these abnormalities as markers for a positive diagnosis of IBS. New and promising drugs for the treatment of IBS with constipation as the predominant symptom are currently on the market, and the treatment results have been satisfactory thus far.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24580043     DOI: 10.1586/17474124.2014.888952

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  21 in total

Review 1.  Recent developments in the pathophysiology of irritable bowel syndrome.

Authors:  Magdy El-Salhy
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

2.  Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities.

Authors:  Magdy El-Salhy; Jan Gunnar Hatlebakk; Trygve Hausken
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

Review 3.  Diet in irritable bowel syndrome.

Authors:  Magdy El-Salhy; Doris Gundersen
Journal:  Nutr J       Date:  2015-04-14       Impact factor: 3.271

4.  Stomach antral endocrine cells in patients with irritable bowel syndrome.

Authors:  Magdy El-Salhy; Odd Helge Gilja; Jan Gunnar Hatlebakk; Trygve Hausken
Journal:  Int J Mol Med       Date:  2014-08-08       Impact factor: 4.101

5.  Changes in small intestinal chromogranin A-immunoreactive cell densities in patients with irritable bowel syndrome after receiving dietary guidance.

Authors:  Tarek Mazzawi; Magdy El-Salhy
Journal:  Int J Mol Med       Date:  2016-03-11       Impact factor: 4.101

6.  Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21st century.

Authors:  Magdy El-Salhy; Tanisa Patcharatrakul; Sutep Gonlachanvit
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

7.  Effect of dietary management on the gastric endocrine cells in patients with irritable bowel syndrome.

Authors:  T Mazzawi; T Hausken; D Gundersen; M El-Salhy
Journal:  Eur J Clin Nutr       Date:  2014-08-06       Impact factor: 4.016

8.  Increased gastric chromogranin A cell density following changes to diets of patients with irritable bowel syndrome.

Authors:  Tarek Mazzawi; Doris Gundersen; Trygve Hausken; Magdy El-Salhy
Journal:  Mol Med Rep       Date:  2014-08-18       Impact factor: 2.952

9.  Increased chromogranin a cell density in the large intestine of patients with irritable bowel syndrome after receiving dietary guidance.

Authors:  Tarek Mazzawi; Doris Gundersen; Trygve Hausken; Magdy El-Salhy
Journal:  Gastroenterol Res Pract       Date:  2015-03-30       Impact factor: 2.260

10.  Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome.

Authors:  T Mazzawi; T Hausken; D Gundersen; M El-Salhy
Journal:  Eur J Clin Nutr       Date:  2015-11-25       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.